MC38-luc Orthotopic Mouse Model Service for Colon Cancer

The MC38-luc orthotopic mouse model pairs the highly immunogenic, C57BL/6-derived MC38 colon adenocarcinoma with firefly luciferase reporter technology, enabling real-time, quantitative tracking of tumor establishment, progression, and therapeutic response within an immunocompetent colonic microenvironment. Alfa Cytology constructs and manages this orthotopic allograft platform with authenticated luciferase-expressing cell stocks, standardized cecal wall or rectal submucosal implantation protocols, and integrated IVIS bioluminescence imaging infrastructure, delivering temporally resolved in vivo datasets that capture tumor growth kinetics, treatment-induced regression, and immune-mediated rejection patterns with unprecedented longitudinal fidelity.

Overview of MC38-luc Orthotopic Mouse Model for Colon Cancer

The MC38 cell line is a murine colon adenocarcinoma originally induced in a female C57BL/6 mouse through exposure to the carcinogen 1,2-dimethylhydrazine dihydrochloride (DMH). As a fully murine cell line, MC38 is syngeneic with C57BL/6 hosts, preserving endogenous T-cell, B-cell, NK-cell, and myeloid compartments—an attribute that has established it as the gold-standard preclinical model for evaluating immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies in colorectal malignancy. The luciferase-transduced derivative (MC38-luc) was generated by lentiviral transduction of the firefly (Photinus pyralis) luciferase gene under constitutive CMV promoter control, with puromycin selection ensuring stable reporter expression across passages. This optical reporting capability enables non-invasive, quantitative monitoring of tumor burden through D-luciferin substrate administration and IVIS spectrum detection, transforming static endpoint assays into dynamic, temporally resolved growth curves.

Fig 1. Comparative evaluation of three orthotopic colon cancer implantation techniques. (Lee, Sang Bong, et al., 2025)

Orthotopic implantation of MC38-luc cells into the cecal wall or rectal submucosa of C57BL/6 mice reconstructs the anatomical positioning, peritoneal environment, and lymphatic drainage patterns of clinical colorectal cancer. Tumor cells are typically delivered as a single-cell suspension in 50 µL PBS (2 × 10⁵ cells) via submucosal injection, with reported engraftment rates exceeding 95%. Bioluminescence signals become detectable within 7–10 days post-implantation and correlate strongly with caliper-derived tumor volumes. A distinctive feature of this model is its variable clinical course: approximately 25–35% of mice develop progressive, lethal colorectal cancer, while the remaining animals mount effective adaptive immune responses that drive spontaneous tumor rejection—mimicking the heterogeneous immunotherapy response observed in human MSI-high colorectal cancer patients. This immunogenicity, combined with real-time optical tracking, renders the MC38-luc orthotopic model exceptionally powerful for dissecting mechanisms of immunotherapy sensitivity, resistance, and combination synergy.

Cell Line Information: MC38-luc

The MC38-luc cell line merges the immunogenic colon adenocarcinoma phenotype of the parental MC38 line with a stably integrated firefly luciferase reporter cassette, enabling quantitative optical readouts of tumor burden and treatment response in syngeneic, immunocompetent hosts. The table below consolidates its essential biological, genetic, reporter, and culture parameters:

Our Services

Alfa Cytology offers a comprehensive MC38-luc orthotopic model service encompassing authenticated luciferase-expressing cell line banking, surgical cecal wall or rectal submucosal implantation, serial bioluminescence imaging, therapeutic intervention, immune profiling, and metastasis assessment. Our platform is optimized for immunotherapy development, leveraging the intact C57BL/6 immune system and real-time optical tracking to generate mechanistically rich, temporally resolved datasets that inform your colon cancer drug development strategy.

Workflow of MC38-luc Orthotopic Mouse Model Construction

Establishment of the MC38-luc orthotopic model requires precise surgical technique, rigorous luciferase validation, and calibrated bioluminescence imaging to achieve consistent engraftment and meaningful optical signal kinetics. The protocol proceeds through the following stages:

1. Cell Expansion and Luciferase Validation: MC38-luc cells are propagated under puromycin selection to maintain luciferase expression, authenticated via STR profiling against the C57BL/6 reference, and confirmed mycoplasma-negative. Luciferase activity is quantified in vitro using a D-luciferin luminometric assay to verify reporter functionality and establish baseline photon flux per cell prior to in vivo use. Cells are harvested during logarithmic growth, counted, and resuspended in ice-cold PBS.
2. Recipient Mouse Preparation and Acclimation: Female or male C57BL/6 mice (6–8 weeks old) are quarantined and acclimated for a minimum of 72 hours. Health status is assessed daily, and any mice displaying abnormal behavior or weight loss are excluded from the study prior to cell implantation.
3. Orthotopic Cecal Wall or Rectal Submucosal Injection: Under general anesthesia, either a midline laparotomy is performed to expose the cecum for submucosal injection (2 × 10⁵ cells in 50 µL PBS via 30-gauge needle), or cells are delivered transanally into the rectal submucosa under endoscopic guidance. The cecum is repositioned and the abdominal wall closed in two layers, or the transanal procedure is completed without external incision.
4. Postoperative Care and Monitoring: Mice receive sustained-release buprenorphine for analgesia and are monitored closely during the 48-hour perioperative period. Body weights are recorded daily for the first week and twice weekly thereafter to detect early cachexia or treatment-related toxicity.
5. Baseline Bioluminescence Imaging and Cohort Stratification: At 7–10 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Tumor-bearing mice with detectable bioluminescent signals are stratified by photon flux intensity into homogeneous treatment cohorts, ensuring balanced baseline signal distributions. Mice without detectable signal by day 14 are excluded from analysis.
6. Therapeutic Intervention and Serial Bioluminescence Monitoring: Test compounds are administered according to the predefined regimen. Bioluminescence imaging is performed at regular intervals (typically weekly) to quantify tumor growth dynamics, treatment-induced signal attenuation, and potential regrowth or rejection. Photon flux values are normalized to baseline and plotted as normalized total flux over time. Body weights and clinical signs are recorded concurrently.
7. Endpoint Necropsy and Ex Vivo Confirmation: Upon reaching study endpoints (tumor volume ~1,500 mm³, humane moribund criteria, scheduled termination, or documented tumor rejection), mice are euthanized. The primary tumor is excised, weighed, and photographed. Ex vivo bioluminescence imaging of excised tumors and organs is performed to confirm metastatic dissemination and validate in vivo imaging accuracy. The liver, lungs, mesenteric lymph nodes, and spleen are harvested for metastasis and immune profiling.
8. Histopathological, Immune, and Molecular Analysis: Primary tumors and metastatic lesions are fixed for H&E and immunohistochemistry (CD31, Ki-67, cleaved caspase-3), or processed for flow cytometry to characterize tumor-infiltrating lymphocytes (CD8⁺ T cells, CD4⁺ T cells, Tregs, MDSCs), NK cells, and dendritic cells. Snap-frozen tissues are reserved for Western blot, qPCR, and RNA-seq. Serum cytokines (IFN-γ, TNF-α, IL-6) are quantified by multiplex assay.

Fig 2. MC38-luc Orthotopic Mouse Model construction workflow.

Case Study-MC38-luc Orthotopic Mouse Model Development

In a preclinical program investigating mechanisms of immune checkpoint blockade resistance in microsatellite-stable colorectal cancer, the MC38-luc orthotopic model was employed to evaluate the efficacy of a novel bispecific antibody targeting both PD-1 and LAG-3, administered as monotherapy and in combination with a tumor vaccine adjuvant. Following orthotopic cecal wall implantation and baseline bioluminescence imaging stratification, treatment cohorts received the test bispecific antibody, anti-PD-1 monotherapy, the adjuvant alone, the combination regimen, or vehicle control. Serial bioluminescence imaging revealed rapid and sustained signal attenuation in the bispecific combination cohort within the first two weeks, with several mice achieving complete signal loss indicative of tumor rejection, whereas the anti-PD-1 monotherapy group showed initial response followed by gradual signal rebound in a subset of animals. Flow cytometric analysis of endpoint tumors demonstrated increased CD8⁺ cytotoxic T-cell infiltration and elevated granzyme B expression in the combination-treated group, alongside reduced exhausted T-cell signatures (PD-1⁺ TIM-3⁺). Serum IFN-γ levels were markedly elevated in responders, correlating with bioluminescence regression kinetics. These findings illustrate the model's unique capacity to capture both acute immunotherapy response and delayed resistance emergence through longitudinal optical tracking, providing actionable insights for optimizing next-generation combination strategies in the preclinical space.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your MC38-luc orthotopic colon cancer study provides access to a specialized platform that bridges syngeneic tumor immunology with quantitative bioluminescence imaging. Our distinguishing capabilities include:

• Authenticated MC38-luc cell banking with documented STR profiling, mycoplasma clearance, and passage-controlled expansion to preserve genetic stability, immunogenicity, and luciferase reporter integrity across study cohorts.
• In-house IVIS bioluminescence imaging infrastructure enabling quantitative, non-invasive tumor tracking with normalized photon flux analysis, capturing growth kinetics, treatment response, immune-mediated rejection, and recurrence patterns in real time.
• Skilled surgical team experienced in both cecal wall and rectal submucosal orthotopic implantation with engraftment rates exceeding 95%, ensuring robust statistical power and reproducible tumor signal kinetics.
• Integrated tumor immune profiling via flow cytometry, encompassing T-cell subsets, NK cells, dendritic cells, MDSCs, tumor-associated macrophages, and exhausted T-cell phenotypes with validated antibody panels.
• Flexible immunotherapy study designs supporting immune checkpoint inhibitors, bispecific antibodies, cancer vaccines, adoptive cell therapies, and combination regimens, with imaging schedules synchronized to dosing regimens.
• Dedicated project scientists providing weekly bioluminescence data updates, interim immune profiling reports, and collaborative interpretation of temporal response and resistance trends to align preclinical findings with your clinical development roadmap.

Contact Us

If your preclinical program demands a syngeneic colon cancer model that combines intact C57BL/6 immunity with the power of real-time bioluminescence tracking, we invite you to reach out to us to discuss how Alfa Cytology can design and execute a tailored MC38-luc orthotopic study aligned with your immunotherapy hypotheses. From surgical implantation and serial imaging through comprehensive immune profiling and resistance mechanism analysis, our team is committed to delivering temporally resolved, mechanistically rich data that advance your colon cancer drug development program. Contact us today to initiate your project and leverage our integrated bioluminescence imaging platform for your next-generation therapeutic candidate.

For research use only. Not intended for any clinical use.